|Bid||102.60 x 1400|
|Ask||106.30 x 800|
|Day's Range||103.47 - 106.96|
|52 Week Range||70.80 - 116.97|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||16.55|
|Earnings Date||Feb 20, 2024 - Feb 26, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.33|
Subscribe to Yahoo Finance Plus to view Fair Value for DVA
Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita are included in this Analyst Blog.
Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.